Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A Roswell Park–led phase 1/2 trial found that alternating bevacizumab and pazopanib — two drugs that both block tumor blood vessel growth — nearly tripled progression-free survival compared to standard single-drug therapy in advanced kidney cancer. The combo was especially impressive in favorable-risk patients, where it matched or outperformed pricier immunotherapy combinations. Researchers say the regimen could be a cost-effective alternative for many patients.
A phase 1/2 clinical trial led by Roswell Park Comprehensive Cancer Center has found that combining two VEGF-blocking therapies — bevacizumab (Avastin) and pazopanib (Votrient) — significantly extends survival in patients with advanced clear cell renal cell carcinoma, the most common type of kidney cancer. Published in The Lancet Oncology, this is believed to be the first trial to demonstrate both safety and efficacy for a dual VEGF-blocking regimen in kidney cancer.
The combination works by attacking tumor blood supply from two angles: pazopanib (a tyrosine kinase inhibitor) blocks VEGF signaling, while bevacizumab (a monoclonal antibody) physically removes VEGF from circulation — helping delay the drug resistance that typically builds with single-agent therapy.
By the Numbers:
Why it matters: Current immunotherapy/TKI combinations often fail to improve overall survival in favorable-risk kidney cancer patients. This regimen matched or exceeded those results — at a significantly lower cost — making it a potentially valuable option, especially in resource-limited settings or for patients who cannot tolerate immunotherapy.
